Cidara Therapeutics to Present New Data on Novel drug-Fc conjugate CD388 at IDWeek 2023
SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology…
SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology…
SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology…
Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting…
Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting…
Following the reverse share split, the Company will have approximately 521,090 Ordinary Shares issued and…
Following the reverse share split, the Company will have approximately 521,090 Ordinary Shares issued and…
FDA assigns GDUFA goal date of April 29, 2024 Milestone builds upon PharmaTher’s commitment toward…
FDA assigns GDUFA goal date of April 29, 2024 Milestone builds upon PharmaTher’s commitment toward…
– Eleven patients enrolled overall in trial to date, with enrollment progressing faster than anticipated…
– Eleven patients enrolled overall in trial to date, with enrollment progressing faster than anticipated…
BEDMINSTER, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) — Matinas BioPharma (NYSE American: MTNB), a clinical-stage…
BEDMINSTER, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) — Matinas BioPharma (NYSE American: MTNB), a clinical-stage…
Patients on combination treatment with UBX1325 and aflibercept from weeks 24-48 maintained vision gains achieved…
Patients on combination treatment with UBX1325 and aflibercept from weeks 24-48 maintained vision gains achieved…
John will lead the company as CEO to explore the potential of a novel therapeutic…
John will lead the company as CEO to explore the potential of a novel therapeutic…
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq:…
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq:…
Financing led by Perceptive Xontogeny Venture Funds, SR One, and Eventide Asset Management, with participation…
Financing led by Perceptive Xontogeny Venture Funds, SR One, and Eventide Asset Management, with participation…